| ABSTRACT Objective: To evaluate the clinical effectiveness, microbiological eradication and adverse reactions of tigecycline combined with cefoperazone sulbactam against cefoperazone sulbactam caused by multidrug/extensively drug resistant Acinetobacter baumannii in seriously pneumonia patients.Methods:Randomized controlled clinical trials were screened by searching some databases such as WanFang Data, CNKI, SinoMed, VIP, PubMed, Embase, The Cochrane Library, Web of science (SCI) up to October 2017. Then two reviewers independently accessed the quality of those literatures by the Risk of bias table Tool which conforming to included and exclusion standards and extracted the required information. Meta analyses were conducted by using RevMan 5.2 software. Results: 9 RCTs were included with a total of 757 patients. The results of Meta analysis showed that the combination therapy group was superior to the monotherapy group on the effective rates (OR=4.68, 95%CI: 3.07 7.15, P<0.000 01) and microbial clearance rates (OR=2.31, 95%CI: 1.64 3.27, P<0.000 01). The incidence of adverse drug reactions of two groups had no statistically significant differences (OR=1.00, 95%CI: 0.52 1.93, P=0.99). Conclusion:The combination therapy showed better clinical and microbial clearance rates than the monotherapy without increasing the risk of adverse reactions, which is much better in the pneumonia caused by multidrug/extensively drug resistant Acinetobacter baumannii. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify the above conclusion. |
